scholarly article | Q13442814 |
P50 | author | Michael A. Jakupec | Q38800373 |
Samuel M. Meier | Q39186748 | ||
Dominique Luneau | Q56418800 | ||
Gabriel E Büchel | Q57028497 | ||
Ghenadie Novitchi | Q57394396 | ||
P2093 | author name string | Erwann Jeanneau | |
Vladimir B Arion | |||
Jean-Bernard Tommasino | |||
Constantin Turta | |||
Maria Novak | |||
Olesea Cuzan | |||
Anatolie Gavriluta | |||
P2860 | cites work | A short history of SHELX | Q25938995 |
Similar Biological Activities of Two Isostructural Ruthenium and Osmium Complexes | Q27650404 | ||
Nitric oxide and inflammation | Q28196548 | ||
Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis | Q33260994 | ||
[Os(IV)Cl(5)(Hazole)](-) complexes: synthesis, structure, spectroscopic properties, and antiproliferative activity | Q33511495 | ||
Nitric oxide (NO): an effector of apoptosis | Q33771673 | ||
Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy | Q34014638 | ||
Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A. | Q34123753 | ||
Role of nitric oxide in inflammation | Q34418998 | ||
Ruthenium- and Osmium-Arene Complexes of 2-Substituted Indolo[3,2-c]quinolines: Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity | Q34498243 | ||
From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). | Q34511975 | ||
Mechanistic aspects of the reactions of nitric oxide with transition-metal complexes | Q34593711 | ||
Chemistry of nitric oxide relevant to biology | Q35660847 | ||
Ruthenium antimetastatic agents | Q35972635 | ||
Nitric oxide, cell signaling and cell death | Q36029955 | ||
Metal-based antitumour drugs in the post genomic era. | Q36446191 | ||
Therapeutic potential of nitric oxide in cancer. | Q36528158 | ||
Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities | Q36601025 | ||
Metal-Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation | Q36613535 | ||
Mechanism elucidation of the cis-trans isomerization of an azole ruthenium-nitrosyl complex and its osmium counterpart | Q36904002 | ||
Nitric oxide, apoptosis and macrophage polarization during tumor progression. | Q37166559 | ||
Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers. | Q37340375 | ||
Design of selective neuronal nitric oxide synthase inhibitors for the prevention and treatment of neurodegenerative diseases | Q37372675 | ||
Nitric oxide: a guardian for vascular grafts? | Q37887771 | ||
Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells. | Q39265638 | ||
Organometallic 3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines as potential anticancer agents | Q39451837 | ||
En route to osmium analogues of KP1019: synthesis, structure, spectroscopic properties and antiproliferative activity of trans-[Os(IV)Cl4(Hazole)2] | Q39510416 | ||
A new nitrosyl ruthenium complex: synthesis, chemical characterization, in vitro and in vivo antitumor activities and probable mechanism of action | Q39526209 | ||
Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences. | Q39684393 | ||
Synthesis, structure, spectroscopic properties, and antiproliferative activity in vitro of novel osmium(III) complexes with azole heterocycles. | Q39965882 | ||
Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy | Q40053135 | ||
Osmium NAMI-A analogues: synthesis, structural and spectroscopic characterization, and antiproliferative properties. | Q40133724 | ||
Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity. | Q40144221 | ||
KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development--an overview. | Q40337165 | ||
Gases as biological messengers: nitric oxide and carbon monoxide in the brain | Q40701647 | ||
Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. | Q42040747 | ||
Synthesis and structural, spectroscopic, and electrochemical characterization of new ruthenium dimethyl sulfoxide nitrosyls | Q44073581 | ||
A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. | Q44918007 | ||
Reversible N-N coupling of NO ligands on dinuclear ruthenium complexes and subsequent N2O evolution: relevance to nitric oxide reductase. | Q50873870 | ||
Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain | Q59062956 | ||
Osmium(II) and Ruthenium(II) Arene Maltolato Complexes: Rapid Hydrolysis and Nucleobase Binding | Q59986441 | ||
Biomolecule binding vs. anticancer activity: Reactions of Ru(arene)[(thio)pyr-(id)one] compounds with amino acids and proteins | Q60240425 | ||
The Metal−NO Interaction in the Redox Systems [Cl5Os(NO)]n-,n= 1−3, andcis-[(bpy)2ClOs(NO)]2+/+: Calculations, Structural, Electrochemical, and Spectroscopic Results | Q64169747 | ||
Efficacy of new ruthenium complexes against chemically induced autochthonous colorectal carcinoma in rats | Q69690609 | ||
Nitric oxide and its role in apoptosis | Q77164340 | ||
New ruthenium nitrosyl complexes with tris(1-pyrazolyl)methane (tpm) and 2,2'-bipyridine (bpy) coligands. Structure, spectroscopy, and electrophilic and nucleophilic reactivities of bound nitrosyl | Q79212452 | ||
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | osmium | Q751 |
P304 | page(s) | 6273-6285 | |
P577 | publication date | 2013-05-09 | |
P1433 | published in | Inorganic Chemistry | Q902828 |
P1476 | title | Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles | |
P478 | volume | 52 |
Q38792102 | A survey of the mechanisms of action of anticancer transition metal complexes |
Q38851401 | Anticancer Organometallic Osmium(II)-p-cymene Complexes |
Q40786041 | Biological properties of novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles |
Q36287265 | Bis-picolinamide Ruthenium(III) Dihalide Complexes: Dichloride-to-Diiodide Exchange Generates Single trans Isomers with High Potency and Cancer Cell Selectivity |
Q37148450 | Dicopper(II) and dizinc(II) complexes with nonsymmetric dinucleating ligands based on indolo[3,2-c]quinolines: synthesis, structure, cytotoxicity, and intracellular distribution. |
Q36026159 | Functionalized Benzimidazole Scaffolds: Privileged Heterocycle for Drug Design in Therapeutic Medicine. |
Q38844730 | Heteropentanuclear Oxalato-Bridged nd-4f (n=4, 5) Metal Complexes with NO Ligand: Synthesis, Crystal Structures, Aqueous Stability and Antiproliferative Activity |
Q60240408 | Organoruthenium and Osmium Anticancer Complexes Bearing a Maleimide Functional Group: Reactivity to Cysteine, Stability, and Cytotoxicity |
Q58117720 | Osmium-Nitrosyl Oxalato-Bridged Lanthanide-Centered Pentanuclear Complexes - Synthesis, Crystal Structures and Magnetic Properties |
Q39022215 | Ruthenium-nitrosyl complexes with glycine, L-alanine, L-valine, L-proline, D-proline, L-serine, L-threonine, and L-tyrosine: synthesis, X-ray diffraction structures, spectroscopic and electrochemical properties, and antiproliferative activity |
Q47743532 | cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339. |
Search more.